A Comparison of Immediate with Deferred Zidovudine Therapy for Asymptomatic HIV-Infected Adults with CD4 Cell Counts of 500 or More per Cubic Millimeter
Open Access
- 17 August 1995
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 333 (7), 401-407
- https://doi.org/10.1056/nejm199508173330701
Abstract
The clinical benefits of zidovudine remain unproved in patients with asymptomatic human immunodeficiency virus (HIV) infection when CD4 cell counts exceed 500 per cubic millimeter. We compared zidovudine therapy given immediately with deferred therapy in such subjects.Keywords
This publication has 15 references indexed in Scilit:
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials GroupPublished by American Medical Association (AMA) ,1994
- Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infectionThe Lancet, 1994
- A Controlled Trial Comparing Continued Zidovudine with Didanosine in Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1992
- A Controlled Trial of Early versus Late Treatment with Zidovudine in Symptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1992
- Surrogate end points in clinical trials.BMJ, 1991
- Adjusting for early treatment termination in comparative clinical trialsStatistics in Medicine, 1990
- Zidovudine in Asymptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1990
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987